Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations

被引：104

作者：

Ahn, Inhye E. ^{[1
]}

Tian, Xin ^{[1
]}

Wiestner, Adrian ^{[1
]}

机构：

[1] NHLBI, Bldg 10, Bethesda, MD 20892 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 05期

关键词：

CLL;

D O I：

10.1056/NEJMc2005943

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with chronic lymphocytic leukemia with chromosome 17 abnormalities have a worse prognosis than those without such alterations. In this phase 2 study, patients who received continuous ibrutinib had a durable response that continued after 6.5 years in some patients.

引用

页码：498 / 500

页数：3

共 5 条

[1] Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study [J].

Ahn, Inhye E. ;

Farooqui, Mohammed Z. H. ;

Tian, Xin ;

Valdez, Janet ;

Sun, Clare ;

Soto, Susan ;

Lotter, Jennifer ;

Housel, Stephanie ;

Stetler-Stevenson, Maryalice ;

Yuan, Constance M. ;

Maric, Irina ;

Calvo, Katherine R. ;

Nierman, Pia ;

Hughes, Thomas E. ;

Saba, Nakhle S. ;

Marti, Gerald E. ;

Pittaluga, Stefania ;

Herman, Sarah E. M. ;

Niemann, Carsten U. ;

Pedersen, Lone B. ;

Geisler, Christian H. ;

Childs, Richard ;

Aue, Georg ;

Wiestner, Adrian .

BLOOD, 2018, 131 (21) :2357-2366

[2] Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions [J].

Fischer, K. ;

Al-Sawaf, O. ;

Bahlo, J. ;

Fink, A. -M. ;

Tandon, M. ;

Dixon, M. ;

Robrecht, S. ;

Warburton, S. ;

Humphrey, K. ;

Samoylova, O. ;

Liberati, A. M. ;

Pinilla-Ibarz, J. ;

Opat, S. ;

Sivcheva, L. ;

Du, K. Le ;

Fogliatto, L. M. ;

Niemann, C. U. ;

Weinkove, R. ;

Robinson, S. ;

Kipps, T. J. ;

Boettcher, S. ;

Tausch, E. ;

Humerickhouse, R. ;

Eichhorst, B. ;

Wendtner, C. -M. ;

Langerak, A. W. ;

Kreuzer, K. -A. ;

Ritgen, M. ;

Goede, V. ;

Stilgenbauer, S. ;

Mobasher, M. ;

Hallek, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (23) :2225-2236

[3] Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study [J].

O'Brien, Susan ;

Jones, Jeffrey A. ;

Coutre, Steven E. ;

Mato, Anthony R. ;

Hillmen, Peter ;

Tam, Constantine ;

Osterborg, Anders ;

Siddiqi, Tanya ;

Thirman, Michael J. ;

Furman, Richard R. ;

Ilhan, Osman ;

Keating, Michael J. ;

Call, Timothy G. ;

Brown, Jennifer R. ;

Stevens-Brogan, Michelle ;

Li, Yunfeng ;

Clow, Fong ;

James, Danelle F. ;

Chu, Alvina D. ;

Hallek, Michael ;

Stilgenbauer, Stephan .

LANCET ONCOLOGY, 2016, 17 (10) :1409-1418

[4] Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia [J].

Shanafelt, T. D. ;

Wang, X. V. ;

Kay, N. E. ;

Hanson, C. A. ;

O'Brien, S. ;

Barrientos, J. ;

Jelinek, D. F. ;

Braggio, E. ;

Leis, J. F. ;

Zhang, C. C. ;

Coutre, S. E. ;

Barr, P. M. ;

Cashen, A. F. ;

Mato, A. R. ;

Singh, A. K. ;

Mullane, M. P. ;

Little, R. F. ;

Erba, H. ;

Stone, R. M. ;

Litzow, M. ;

Tallman, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (05) :432-443

[5] Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL [J].

Woyach, J. A. ;

Ruppert, A. S. ;

Heerema, N. A. ;

Zhao, W. ;

Booth, A. M. ;

Ding, W. ;

Bartlett, N. L. ;

Brander, D. M. ;

Barr, P. M. ;

Rogers, K. A. ;

Parikh, S. A. ;

Coutre, S. ;

Hurria, A. ;

Brown, J. R. ;

Lozanski, G. ;

Blachly, J. S. ;

Ozer, H. G. ;

Major-Elechi, B. ;

Fruth, B. ;

Nattam, S. ;

Larson, R. A. ;

Erba, H. ;

Litzow, M. ;

Owen, C. ;

Kuzma, C. ;

Abramson, J. S. ;

Little, R. F. ;

Smith, S. E. ;

Stone, R. M. ;

Mandrekar, S. J. ;

Byrd, J. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) :2517-2528

← 1 →